Organon & Co. (NYSE:OGN - Get Free Report) shares hit a new 52-week low on Friday . The company traded as low as $13.25 and last traded at $13.18, with a volume of 785212 shares trading hands. The stock had previously closed at $14.45.
Wall Street Analyst Weigh In
A number of analysts have recently commented on OGN shares. Barclays dropped their price objective on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Morgan Stanley dropped their price target on Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating for the company in a research note on Wednesday. Finally, TD Cowen upgraded Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Organon & Co. currently has a consensus rating of "Hold" and a consensus target price of $20.60.
Read Our Latest Stock Report on Organon & Co.
Organon & Co. Trading Up 8.1 %
The stock has a market capitalization of $3.25 billion, a PE ratio of 3.78, a PEG ratio of 0.90 and a beta of 0.73. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The business's 50-day moving average is $14.91 and its two-hundred day moving average is $15.85.
Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. On average, analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.
Organon & Co. Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were given a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 8.89%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is 33.63%.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB increased its stake in Organon & Co. by 32.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock worth $41,000 after buying an additional 672 shares during the period. Treasurer of the State of North Carolina grew its stake in shares of Organon & Co. by 0.6% during the fourth quarter. Treasurer of the State of North Carolina now owns 113,120 shares of the company's stock valued at $1,688,000 after acquiring an additional 710 shares in the last quarter. Beam Wealth Advisors Inc. increased its position in shares of Organon & Co. by 3.9% during the fourth quarter. Beam Wealth Advisors Inc. now owns 18,888 shares of the company's stock worth $282,000 after acquiring an additional 717 shares during the last quarter. HighTower Advisors LLC lifted its stake in shares of Organon & Co. by 0.5% in the fourth quarter. HighTower Advisors LLC now owns 163,440 shares of the company's stock worth $2,439,000 after acquiring an additional 855 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its stake in shares of Organon & Co. by 4.9% in the fourth quarter. CIBC Asset Management Inc now owns 25,523 shares of the company's stock worth $381,000 after acquiring an additional 1,184 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.
About Organon & Co.
(
Get Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
See Also
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
